FDA Cancer Trial Guidelines: Prioritizing Overa...

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift foc...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...
Social Media Policy Action: Protecting Youth from Cognitive Risks
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...
Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerat...